<!DOCTYPE html>
<html lang="en" dir="ltr" xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office">

<head>
    <!-- HTML EMAIL -->
    <!-- PROJECT NAME: Besremi-May-[EM2] -->
    <!-- SUBJECT LINE: BESREMiÂ® delivers long-term polycythemia vera (PV) control -->
    <!-- TEST INFO: paste here the litmus or EOA link for this project -->
    <!-- BACKGROUND COLOR: #FFFFFF, EMAIL WIDTH: 640  -->
    <meta charset="utf-8">
    <meta name="viewport" content="width=device-width, initial-scale=1, user-scalable=yes">
    <meta name="format-detection" content="telephone=no, date=no, address=no, email=no, url=no">
    <meta name="x-apple-disable-message-reformatting">
    <meta name="color-scheme" content="light only">
    <meta name="supported-color-schemes" content="light only">
    <!--[if !mso]><!-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge" />
    <!--<![endif]-->
    <title>BESREMi </title>
    <!--Custom Fonts-->
    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
    <link href="https://fonts.googleapis.com/css2?family=Montserrat:ital,wght@0,100..900;1,100..900&display=swap" rel="stylesheet">

    <style type="text/css">
        /* STYLES HERE! */
        /* RESET CLASSES */
        html {
            -webkit-text-size-adjust: none;
            -webkit-font-smoothing: antialiased;
        }

        body {
            margin: 0;
            padding: 0;
            -ms-text-size-adjust: 100%;
            -webkit-text-size-adjust: 100%;
        }

        sup {
            line-height: 1.4;
            font-size: 62%;
            vertical-align: top;
            mso-text-raise: 52%;
        }

        sub {
            font-size: 9px;
            line-height: 10px;
        }

        .montserrat-regular {
            font-family: "Montserrat", serif;
            font-optical-sizing: auto;
            font-weight: 400;
            font-style: normal;
        }

        .montserrat-bold {
            font-family: "Montserrat", serif;
            font-optical-sizing: auto;
            font-weight: 700;
            font-style: normal;
            ;
        }

        .montserrat-black {
            font-family: "Montserrat", serif;
            font-optical-sizing: auto;
            font-weight: 900;
            font-style: normal;
        }

        html,
        body,
        table,
        table td {
            font-family: Arial, Helvetica, sans-serif;
        }

        img {
            border: 0 none;
            height: auto;
            line-height: 100%;
            outline: none;
            text-decoration: none;
            display: block;
        }

        a {
            outline: 0;
            text-decoration: none !important;
        }

        a,
        a:active,
        a:link,
        a:visited {
            color: #000000;
        }

        a img {
            border: none;
        }

        a.phone {
            text-decoration: none;
            color: #000001 !important;
            pointer-events: auto;
            cursor: default;
        }

        .kill-blue-links a {
            color: inherit !important;
            text-decoration: none !important;
        }

        /* phone link, use as wrapper on phone numbers */
        /* GENERAL STYLE RESETS */
        body,
        #bodyTable {
            height: 100% !important;
            width: 100% !important;
            margin: 0;
            padding: 0;
        }

        img,
        a img {
            border: 0;
            outline: none;
            text-decoration: none;
        }

        .imageFix {
            display: block;
        }

        table,
        td {
            border-collapse: collapse;
        }

        /* What it does: Remove spaces around the email design added by some email clients. */
        /* Beware: It can remove the padding / margin and add a background color to the compose a reply window. */
        html,
        body {
            margin: 0 auto !important;
            padding: 0 !important;
            height: 100% !important;
            width: 100% !important;
        }

        /* What it does: Stops email clients resizing small text. */
        * {
            -ms-text-size-adjust: 100%;
            -webkit-text-size-adjust: 100%;
        }

        /* What it does: Centers email on Android 4.4 */
        div[style*="margin: 16px 0"] {
            margin: 0 !important;
        }

        /* What it does: Stops Outlook from adding extra spacing to tables. */
        table,
        td {
            mso-table-lspace: 0pt !important;
            mso-table-rspace: 0pt !important;
        }

        /* What it does: Fixes webkit padding issue. */
        table {
            border: 0;
            border-spacing: 0;
            border-collapse: collapse
        }

        /* What it does: Forces Samsung Android mail clients to use the entire viewport. */
        #MessageViewBody,
        #MessageWebViewDiv {
            width: 100% !important;
        }

        /* What it does: Uses a better rendering method when resizing images in IE. */
        img {
            -ms-interpolation-mode: bicubic;
        }

        /* What it does: Prevents Windows 10 Mail from underlining links despite inline CSS. Styles for underlined links should be inline. */
        a {
            text-decoration: none;
        }

        /* What it does: A work-around for email clients automatically linking certain text strings. */
        /* iOS */
        a[x-apple-data-detectors],
        .unstyle-auto-detected-links a,
        .aBn {
            border-bottom: 0 !important;
            cursor: default !important;
            color: inherit !important;
            text-decoration: none !important;
            font-size: inherit !important;
            font-family: inherit !important;
            font-weight: inherit !important;
            line-height: inherit !important;
        }

        u+#body a,
        /* Gmail */
        #MessageViewBody a

        /* Samsung Mail */
            {
            color: inherit;
            text-decoration: none;
            font-size: inherit;
            font-family: inherit;
            font-weight: inherit;
            line-height: inherit;
        }

        /* What it does: Prevents Gmail from changing the text color in conversation threads. */
        .im {
            color: inherit !important;
        }

        /* What it does: Prevents Gmail from displaying an download button on large, non-linked images. */
        .a6S {
            display: none !important;
            opacity: 0.01 !important;
        }

        /* If the above doesn't work, add a .g-img class to any image in question. */
        img.g-img+div {
            display: none !important;
        }

        u~div img+div>div {
            display: none
        }

        /* What it does: Removes right gutter in Gmail iOS app. */
        /* Outlook.com */
        #outlook a {
            padding: 0;
        }

        /* Center your email in Outlook.com */
        .ExternalClass {
            width: 100%;
        }

        /* Overwrite Outlook.com's Embedded CSS */
        table {
            border-collapse: separate;
        }

        a,
        a:link,
        a:visited {
            text-decoration: none;
            /* OUTLOOK DEFAULT LINK COLOR */
            color: #0000FF;
        }

        .ms-outlook-linkify {
            color: inherit !important;
        }

        a:hover {
            text-decoration: underline;
        }

        h2,
        h2 a,
        h2 a:visited,
        h3,
        h3 a,
        h3 a:visited,
        h4,
        h5,
        h6,
        .t_cht {
            color: #000 !important;
        }

        .ExternalClass p,
        .ExternalClass span,
        .ExternalClass font,
        .ExternalClass td {
            line-height: 100%;
        }

        .ReadMsgBody {
            width: 100%;
            background-color: #FFFFFF;
        }

        /* Microsoft Outlook desktop clients */
        table {
            mso-table-lspace: 0pt;
            mso-table-rspace: 0pt;
        }

        td {
            mso-line-height-rule: exactly;
        }

        img {
            -ms-interpolation-mode: bicubic;
        }

        [data-outlook-cycle],
        a[x-apple-data-detectors],
        [x-apple-data-detectors-type="calendar-event"] {
            -webkit-text-decoration-color: inherit !important;
            color: inherit !important;
            text-decoration: none !important;
            font-size: inherit !important;
            font-family: inherit !important;
            font-weight: inherit !important;
            line-height: inherit !important;
        }

        /* Gmail fixes*/
        /* RESET CLASSES */
        /* RESPONSIVE CLASSES */
        .no-break {
            white-space: nowrap !important;
        }

        .hide-for-desktop {
            display: none !important;
        }

        /* display: none; max-height: 0px; overflow: hidden; visibility: hidden; mso-hide: all; */
        @media screen and (max-width: 640px) {
            .hide-for-desktop {
                display: initial !important;
            }

            .hide-for-mobile,
            .hide-for-mobile * {
                display: none !important;
            }

            .mobile-side-padding {
                padding-left: 20px !important;
                padding-right: 20px !important;
                max-width: 100% !important;
            }

            .no-padding {
                padding: 0 !important;
            }

            .full-width {
                width: 100% !important;
            }

            img.fluid-on-mobile {
                width: 100% !important;
                height: auto !important;
            }

            .center {
                text-align: center !important;
            }

            .center>img {
                display: block !important;
                margin-right: auto !important;
                margin-left: auto !important;
            }

            .column {
                display: block !important;
                width: 100% !important;
            }

            .column-top {
                display: table-header-group !important;
                width: 100% !important;
            }

            .column-bottom {
                display: table-footer-group !important;
                width: 100% !important;
            }

            .pt10 {
                padding-top: 10px !important;
            }

            .pb20 {
                padding-bottom: 20px !important;
            }
            .noBorder {
                border: none !important;
            }

            /* Add your responsive classes here */

            /* if class defined with *[class~=] then you can combine names i.e: class="mobile-side-padding center"*/
        }

        @media only screen and (max-width: 414px) {}
        @media only screen and (max-width: 375px) {
            .btnFull img 
            {
                width: 100% !important;
                height: auto !important;
            }
        }
        @media only screen and (max-width: 360px) {}
        @media only screen and (max-width: 320px) {}
        
        

        /*
    ðð DARK MODE
    <meta name="color-scheme" content="light dark">
    <meta name="supported-color-schemes" content="light dark">
    :root {
        color-scheme: light dark;
        supported-color-schemes: light dark;
    }
    @media (prefers-color-scheme: dark) {
          a,td,th,img,h1,h2,h3,h4,h5,h6,em,strong,i,b,u,span,div,ul,ol,li
          {
               color: #DDDDDD !important;
          }
          body, table
          {
               background-color: #161616 !important;
          }
          .show-for-dark-mode { 
               display: block !important;
               visibility: visible !important;
          }
          .hide-for-dark-mode { 
               display: none !important; 
               visibility: hidden !important; 
          }
    }
    [data-ogsc] .show-for-dark-mode { 
        display: block !important;
        visibility: visible !important;
    }  
    [data-ogsc] .hide-for-dark-mode { 
        display: none !important; 
        visibility: hidden !important; 
    }
    */
        /* RESPONSIVE CLASSES */
    </style>
    <style>
        @supports selector(:has(*)) {
            .preheader:has(.AE_customText) {
            display:block !important;
            opacity:1 !important;
            visibility:visible !important;
            overflow:unset !important;
            }
        }
    </style>
    <!--[if gte mso 16]>
    <style>
      /* https://webdesign.tutsplus.com/how-to-fix-outlook-dark-mode-problems--cms-37718t */
      .keep-black {mso-style-textfill-type:gradient;mso-style-textfill-fill-gradientfill-stoplist:"0 \#000000 1 100000\,99000 \#000000 1 100000";color: #ffffff !important;}
      .keep-white {mso-style-textfill-type:gradient;mso-style-textfill-fill-gradientfill-stoplist:"0 \#FFFFFF 0 100000\,100000 \#FFFFFF 0 100000";color:#000000 !important;}
    </style> 
    <![endif]-->
    <!--[if gte mso 9]>
    <noscript>
    <xml>
      <o:OfficeDocumentSettings>
        <o:AllowPNG/>
        <o:PixelsPerInch>96</o:PixelsPerInch>
      </o:OfficeDocumentSettings>
    </xml>
    </noscript>
    <![endif]-->
</head>

<body id="body" style="width:100%; margin:0; padding:0; background-color: #FFFFFF; -webkit-text-size-adjust:100%; -ms-text-size-adjust:100%;">
<!-- PREHEADER -->
 <div>
    <span class="preheader" style="font-size:0px;line-height:0px;max-height:0px;max-width:0px;mso-hide:all !important;overflow:hidden;visibility:hidden;display:none;">
        {{customText[Discover long-term control with BESREMi&reg;|Explore a different treatment approach for your patients with first-line BESREMi&reg;|Learn what sets BESREMi&reg; apart for your patients]}}
    </span>
</div>
<!--==============-->
<!-- PREVIEW TEXT -->
<!--==============-->
<div style="display: none !important; visibility: hidden; mso-hide:all;">
&#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847;&#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847;&#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847;&#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847;&#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847;&#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847;&#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847;&#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847;&#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847;&#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847;&#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847;&#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847;&#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847;&#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847;&#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847;&#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847; &#8199;&#847;&shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &shy; &nbsp;
</div>

    
    <div role="article" aria-roledescription="email" lang="en" style="-webkit-text-size-adjust:100%;-ms-text-size-adjust:100%; background-color: #FFFFFF;">
        <!-- BODY TABLE: uses the width of the viewport. It defines the background color. -->
        <table cellpadding="0" cellspacing="0" role="presentation" border="0" style="margin:0; padding:0; width:100%; border:0; border-spacing:0; background-color: #FFFFFF;">
            <tr>
                <td valign="top">
                    <!--=====================-->
                    <!-- WRAPPER TABLE START -->
                    <!--=====================-->
                    <table cellpadding="0" cellspacing="0" role="presentation" border="0" align="center" width="640" class="full-width"
                        style="max-width: 640px; width:100%; background-color: #FFFFFF;">
                        <tr>
                            <td valign="top" style="vertical-align: top;">
                                <!-- CONTENT STARTS HERE -->

                                <!-- SECTION: Header -->
                                <table width="100%" role="presentation" border="0" cellspacing="0" cellpadding="0" align="center"
                                    style="border-collapse: collapse; mso-table-lspace: 0pt; mso-table-rspace: 0pt;">
                                    <tr>
                                        <td align="center" valign="top" style="padding: 0; font-weight: normal; border-collapse: collapse; mso-height-rule: exactly;">
                                            <img src="https://production-stage.s3.us-east-1.amazonaws.com/emails/Spectrum/BESREMi/May-Test/EM2/images/header.jpg"
                                                width="100%" alt="BESREMi"
                                                style="display: block; text-align: center; color: #000000; font-family: Arial, Helvetica, sans-serif; font-size:14px; line-height:16px; font-weight: bold; margin:0; padding:0; border:none; height: auto; max-width: 100%;"
                                                border="0" />
                                        </td>
                                    </tr>
                                </table>


                                <table width="100%" role="presentation" border="0" cellspacing="0" cellpadding="0" align="center"
                                    style="border-collapse: collapse; mso-table-lspace: 0pt; mso-table-rspace: 0pt;">
                                    <tr>
                                        <td class="mobile-side-padding" align="center" valign="top" style="padding: 0 45px 30px; border-collapse: collapse; mso-height-rule: exactly;">
                                            <!-- Internal Content -->
                                            <table width="100%" role="presentation" border="0" cellspacing="0" cellpadding="0" align="center"
                                                style="border-collapse: collapse; mso-table-lspace: 0pt; mso-table-rspace: 0pt;">
                                                <tr>
                                                    <td class="montserrat-black" align="left" valign="top"
                                                        style="padding: 26px 0 0; font-family: 'Montserrat', Arial, Helvetica, sans-serif; font-size: 14px; line-height: 17px; color: #000000; font-weight: 800; font-style: normal; border-collapse: collapse; mso-height-rule: exactly; ">
                                                        Consider BESREMi for long-term polycythemia vera (PV) control
                                                    </td>
                                                </tr>

                                                <tr>
                                                    <td class="montserrat-black" align="left" valign="top"
                                                        style="padding: 25px 0 0; font-family: 'Montserrat', Arial, Helvetica, sans-serif; font-size: 14px; line-height: 17px; color: #000000; font-weight: 400; font-style: normal; border-collapse: collapse; mso-height-rule: exactly; ">
                                                        Dear {{accTitle}} {{accLname}},
                                                    </td>
                                                </tr>

                                                <tr>
                                                    <td class="montserrat-regular" align="left" valign="top"
                                                        style="padding: 25px 0 0; font-family: 'Montserrat', Arial, Helvetica, sans-serif; font-size: 14px; line-height: 17px; color: #000000; font-weight: 400; font-style: normal; border-collapse: collapse; mso-height-rule: exactly; ">
                                                        {{customText[I&rsquo;m sharing this in advance of our upcoming meeting. |I&rsquo;m sorry I missed you. |I&rsquo;m reaching out with information that may support your PV patients.]}}
                                                    </td>
                                                </tr>

                                                <tr>
                                                    <td class="montserrat-regular" align="left" valign="top"
                                                        style="padding: 25px 0 0; font-family: 'Montserrat', Arial, Helvetica, sans-serif; font-size: 14px; line-height: 17px; color: #000000; font-weight: 400; font-style: normal; border-collapse: collapse; mso-height-rule: exactly; ">
                                                        For your patients with polycythemia vera (PV), I wanted to share that ropeginterferon alfa&#8209;2b&#8209;njft (BESREMi) is now listed as a preferred first&#8209;line cytoreductive therapy in the latest 
                                                        <a href="https://www.besremihcp.com/wp-content/uploads/2025/02/NCCN-Flashcard-v1-2025_Digital-1.pdf" target="_blank"><u style="color: #0e3d4e; font-weight: 700;">NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines<sup>&reg;</sup>)</u></a>
                                                        for both low&#8209;risk (symptomatic) and high&#8209;risk&nbsp;PV.<sup>1</sup>
                                                    </td>
                                                </tr>        

                                                <tr>
                                                    <td class="montserrat-regular" align="left" valign="top"
                                                        style="padding: 25px 0 0; font-family: 'Montserrat', Arial, Helvetica, sans-serif; font-size: 14px; line-height: 17px; color: #000000; font-weight: 400; font-style: normal; border-collapse: collapse; mso-height-rule: exactly; ">
                                                        As you may know, BESREMi is the only innovative, single-site monopegylated interferon that delivered efficacy over a 7.5-year clinical trial.<sup>2,3</sup> The PEGINVEA study was a multicenter, single-arm trial conducted to evaluate the dosing, tolerability, and efficacy of BESREMi in patients with PV (N=51).<sup>2</sup>
                                                    </td>
                                                </tr>

                                                <tr>
                                                    <td class="montserrat-regular" align="left" valign="top"
                                                        style="padding: 25px 0 0; font-family: 'Montserrat', Arial, Helvetica, sans-serif; font-size: 14px; line-height: 17px; color: #0e3d4e; font-weight: 800; font-style: normal; border-collapse: collapse; mso-height-rule: exactly; ">
                                                        Robust and durable rates of complete hematologic response<sup>2*</sup>
                                                    </td>
                                                </tr>

                                                <!--IMG-->
                                                <tr>
                                                    <td align="left" valign="top"
                                                        style="padding:10px 0 0 20px; border-collapse: collapse; mso-height-rule: exactly; ">
                                                        <!-- ð¼ï¸ IMG -->
                                                        <img src="https://production-stage.s3.us-east-1.amazonaws.com/emails/Spectrum/BESREMi/May-Test/EM2/images/graph1.png" width="200" alt="80% (41/51) complete hematologic response rate" style="display: block; text-align: center; color: #000000; font-family: Arial, Helvetica, sans-serif; font-size:14px; line-height:16px; font-weight: bold; margin:0; padding:0; border:none; height: auto; max-width: 100%;" border="0" />
                                                    </td>
                                                </tr>

                                                <!--Footenote-->
                                                <tr>
                                                    <td class="montserrat-regular" align="left" valign="top" style="padding: 10px 0px 0; border-collapse: collapse; mso-height-rule: exactly;">
                                                        <table cellspacing="0" cellpadding="0" border="0" width="100%" role="presentation" align="center"
                                                            style="border-collapse:collapse; mso-table-lspace: 0pt; mso-table-rspace: 0pt;">
                                                            <tr>
                                                                <td width="2" align="center" valign="top"
                                                                    style="font-family: 'Montserrat', Arial, Helvetica, sans-serif; font-size: 11px; line-height: 14px; color: #000000; font-weight: 400; font-style: normal; border-collapse: collapse; mso-height-rule: exactly; vertical-align: top;">
                                                                    *</td>
                                                                <td align="left" valign="top"
                                                                    style="padding: 0; font-family: 'Montserrat', Arial, Helvetica, sans-serif; font-size: 11px; line-height: 14px; color: #000000; font-weight: 400; font-style: normal; border-collapse: collapse; mso-height-rule: exactly;">
                                                                    Defined as no phlebotomy in the past 2 months, hematocrit &lt;45%, leukocyte count &le;10 x 10<sup>9</sup>/L, and platelet count &le;400 x 10<sup>9</sup>/L.</td>
                                                            </tr>
                                                        </table>
                                                    </td>
                                                </tr>

                                                <tr>
                                                    <td class="montserrat-regular" align="left" valign="top"
                                                        style="padding: 25px 0 0; font-family: 'Montserrat', Arial, Helvetica, sans-serif; font-size: 14px; line-height: 17px; color: #0e3d4e; font-weight: 800; font-style: normal; border-collapse: collapse; mso-height-rule: exactly; ">
                                                        Comprehensive disease control with zero thromboembolic events<sup>2&dagger;</sup>
                                                    </td>
                                                </tr>

                                                <!--IMG-->
                                                <tr>
                                                    <td  align="left" valign="top"
                                                        style="padding:10px 0 0 20px; border-collapse: collapse; mso-height-rule: exactly; ">
                                                        <!-- ð¼ï¸ IMG -->
                                                        <img src="https://production-stage.s3.us-east-1.amazonaws.com/emails/Spectrum/BESREMi/May-Test/EM2/images/graph2.png" width="270" alt="61% (31/51) achieved comprehensive disease control with zero thromboembolic events" style="display: block; text-align: center; color: #000000; font-family: Arial, Helvetica, sans-serif; font-size:14px; line-height:16px; font-weight: bold; margin:0; padding:0; border:none; height: auto; max-width: 100%;" border="0" />
                                                    </td>
                                                </tr>

                                                <!--Footenote-->
                                                <tr>
                                                    <td class="montserrat-regular" align="left" valign="top" style="padding: 10px 0px 0; border-collapse: collapse; mso-height-rule: exactly;">
                                                        <table cellspacing="0" cellpadding="0" border="0" width="100%" role="presentation" align="center"
                                                            style="border-collapse:collapse; mso-table-lspace: 0pt; mso-table-rspace: 0pt;">
                                                            <tr>
                                                                <td width="2" align="center" valign="top"
                                                                    style="font-family: 'Montserrat', Arial, Helvetica, sans-serif; font-size: 11px; line-height: 14px; color: #000000; font-weight: 400; font-style: normal; border-collapse: collapse; mso-height-rule: exactly; vertical-align: top;">
                                                                    <sup>&dagger;</sup></td>
                                                                <td align="left" valign="top"
                                                                    style="padding: 0; font-family: 'Montserrat', Arial, Helvetica, sans-serif; font-size: 11px; line-height: 14px; color: #000000; font-weight: 400; font-style: normal; border-collapse: collapse; mso-height-rule: exactly;">
                                                                    Defined as no phlebotomy in the past 2 months, hematocrit &lt;45%, leukocyte count &le;10 x 10<sup>9</sup>/L, platelet count &le;400 x 10<sup>9</sup>/L, normal spleen size, and absence of thromboembolic events.</td>
                                                            </tr>
                                                        </table>
                                                    </td>
                                                </tr>

                                                <tr>
                                                    <td class="montserrat-regular" align="left" valign="top"
                                                        style="padding: 25px 0 0; font-family: 'Montserrat', Arial, Helvetica, sans-serif; font-size: 14px; line-height: 17px; color: #0e3d4e; font-weight: 800; font-style: normal; border-collapse: collapse; mso-height-rule: exactly; ">
                                                        BESREMi demonstrated a manageable safety profile in the same 7.5&#8209;year&nbsp;trial
                                                    </td>
                                                </tr> 


                                                <!--List Items-->
                                                <tr>
                                                    <td class="montserrat-regular" align="left" valign="top" style="padding: 10px 0px 0; border-collapse: collapse; mso-height-rule: exactly;">
                                                        <table cellspacing="0" cellpadding="0" border="0" width="100%" role="presentation" align="center"
                                                            style="border-collapse:collapse; mso-table-lspace: 0pt; mso-table-rspace: 0pt;">
                                                            <tr>
                                                                <td width="8" align="center" valign="top"
                                                                    style="font-family: 'Montserrat', Arial, Helvetica, sans-serif; font-size: 14px; line-height: 16px; color: #f2a732; font-weight: 800; font-style: normal; border-collapse: collapse; mso-height-rule: exactly; vertical-align: top;">
                                                                    &#8226;</td>
                                                                <td align="left" valign="top"
                                                                    style="padding: 0 0 7px 5px; font-family: 'Montserrat', Arial, Helvetica, sans-serif; font-size: 14px; line-height: 16px; color: #000000; font-weight: 400; font-style: normal; border-collapse: collapse; mso-height-rule: exactly;">
                                                                    Zero cases of acute myeloid leukemia and 1 case of myelofibrosis over the 7.5&nbsp;years<sup>4</sup>
                                                                </td>
                                                            </tr>
                                                            
                                                            <tr>
                                                                <td width="8" align="center" valign="top"
                                                                    style="font-family: 'Montserrat', Arial, Helvetica, sans-serif; font-size: 14px; line-height: 17px; color: #f2a732; font-weight: 800; font-style: normal; border-collapse: collapse; mso-height-rule: exactly; vertical-align: top;">
                                                                    &#8226;</td>
                                                                <td align="left" valign="top"
                                                                    style="padding: 0 0 0 5px; font-family: 'Montserrat', Arial, Helvetica, sans-serif; font-size: 14px; line-height: 17px; color: #000000; font-weight: 400; font-style: normal; border-collapse: collapse; mso-height-rule: exactly;">
                                                                    Adverse reactions were transient and diminished over time after the first 3&nbsp;months<sup>4</sup>
                                                                </td>
                                                            </tr>
                                                        </table>
                                                    </td>
                                                </tr>

                                                

                                                <tr>
                                                    <td class="montserrat-regular" align="left" valign="top"
                                                        style="padding: 25px 0 0; font-family: 'Montserrat', Arial, Helvetica, sans-serif; font-size: 14px; line-height: 17px; color: #000000; font-weight: 400; font-style: normal; border-collapse: collapse; mso-height-rule: exactly; ">
                                                        If you'd like to review efficacy or safety data ahead of your next PV patient, you can visit <a href="https://www.besremihcp.com/" target="_blank"><u style="color: #0e3d4e;">w&zwj;ww&zwj;.&zwj;BESREMiHCP&zwj;.&zwj;co&zwj;m</u></a>.
                                                    </td> 
                                                </tr>
                                                <tr>
                                                    <td class="montserrat-regular" align="left" valign="top"
                                                        style="padding: 25px 0 0; font-family: 'Montserrat', Arial, Helvetica, sans-serif; font-size: 14px; line-height: 17px; color: #000000; font-weight: 400; font-style: normal; border-collapse: collapse; mso-height-rule: exactly; ">
                                                        Let me know if you&rsquo;d like to connect further. My contact information is&nbsp;below.
                                                    </td> 
                                                </tr>
                                                <tr>
                                                    <td class="montserrat-regular" align="left" valign="top"
                                                        style="padding: 25px 0 0; font-family: 'Montserrat', Arial, Helvetica, sans-serif; font-size: 14px; line-height: 17px; color: #000000; font-weight: 400; font-style: normal; border-collapse: collapse; mso-height-rule: exactly; ">
                                                        {{customText[Email me if you'd like to set up a quick call. |If you&rsquo;d like to meet, reply so we can find a convenient time. |Interested in prescribing? I can email you ordering information.]}}
                                                    </td>
                                                </tr>


                                            </table>
                                            <!-- End Internal Content -->
                                        </td>
                                    </tr>
                                </table>


                                <!--SECTION Banner: Sincerely -->
                                <table width="100%" role="presentation" border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse: collapse; mso-table-lspace: 0pt; mso-table-rspace: 0pt; background-color: #D7F1F6;">
                                    <tr>
                                    <td class="mobile-side-padding" align="left" valign="top" style="padding: 25px 59px 25px 45px;border-collapse: collapse; mso-height-rule: exactly;background-color: #D7F1F6;">

                                        <table width="100%" role="presentation" border="0" cellspacing="0" cellpadding="0" align="center"
                                        style="border-collapse: collapse; mso-table-lspace: 0pt; mso-table-rspace: 0pt; background-color: #D7F1F6;">
                                            <tr>
                                                <td class="montserrat-regular" align="left" valign="top"
                                                    style="padding: 0;font-family: 'Montserrat', Arial, Helvetica, sans-serif; font-size: 14px; line-height: 22px; color: #000000; font-weight: 400; font-style: normal; border-collapse: collapse; mso-height-rule: exactly;background-color: #D7F1F6;">
                                                        <strong>Sincerely,</strong>
                                                        <br />
                                                        <span style="color:#0e3d4e; font-weight: bold;">{{userName}}</span>
                                                        <br />
                                                        {{User.Title}}
                                                        <br />
                                                        {{User.Phone}}
                                                        <br />
                                                        {{userEmailAddress}}
                                                </td>
                                            </tr>
                                            <tr>
                                                <td class="montserrat-regular" align="left" valign="top"
                                                    style="padding: 10px 0 5px; border-collapse: collapse; mso-height-rule: exactly; ">
                                                    <img src="https://production-stage.s3.us-east-1.amazonaws.com/emails/Spectrum/BESREMi/May-Test/EM2/images/PEC-logo.png" width="110" alt="PharmaEssentiaâ¢" style="display: block; text-align: center; color: #000000; font-family: Arial, Helvetica, sans-serif; font-size:14px; line-height:16px; font-weight: bold; margin:0; padding:0; border:none; height: auto; max-width: 100%;" border="0" />
                                                </td>
                                            </tr>
                                        </table>
                                            
                                    </td>
                                    </tr>
                                </table>

                        

                                <!--======ISI=======-->
                                <!-- INDICATION -->
                                <table width="100%" role="presentation" border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse: collapse; mso-table-lspace: 0pt; mso-table-rspace: 0pt;">
                                    <tr>
                                        <td class="mobile-side-padding montserrat-regular" align="left" valign="top"
                                            style="padding: 20px 45px 0;font-family: 'Montserrat', Arial, Helvetica, sans-serif; font-size: 14px; line-height: 17px; color: #000000; font-weight: 400; font-style: normal; border-collapse: collapse; mso-height-rule: exactly;">
                                            <strong style="color: #244C5A; font-weight: 600;">INDICATION</strong> 
                                        </td>
                                    </tr>
                                    <tr>
                                        <td class="mobile-side-padding montserrat-regular" align="left" valign="top"
                                            style="padding: 10px 45px 0;font-family: 'Montserrat', Arial, Helvetica, sans-serif; font-size: 14px; line-height: 17px; color: #000000; font-weight: 400; font-style: normal; border-collapse: collapse; mso-height-rule: exactly;">
                                            BESREMi is indicated for the treatment of adults with polycythemia vera.<br /><br />
                                            <strong style="color: #244C5A; font-weight: 600;">IMPORTANT SAFETY INFORMATION</strong>
                                        </td>
                                    </tr>
                                </table>


                                <!--ISI SECTION-->
                                <table width="100%" role="presentation" border="0" cellspacing="0" cellpadding="0" align="center"
                                    style="border-collapse: collapse; mso-table-lspace: 0pt; mso-table-rspace: 0pt;">
                                    <!--Box Warning Info-->
                                    <tr>
                                        <td class="mobile-side-padding montserrat-regular" align="left" valign="top" style="padding: 10px 45px 0; border-collapse: collapse; mso-height-rule: exactly;">
                                            <!-- TABLE START -->
                                            <table width="100%" role="presentation" border="0" cellspacing="0" cellpadding="0" align="center"
                                                style="border-collapse: collapse; mso-table-lspace: 0pt; mso-table-rspace: 0pt; border: 1px solid #000000;">
                                                <tr>
                                                    <td class="montserrat-regular" align="center" valign="top"
                                                        style="padding: 15px 15px 0; font-family: 'Montserrat', Arial, Helvetica, sans-serif; font-size: 14px; line-height: 17px; color: #000000; font-weight: 400; font-style: normal; border-collapse: collapse; mso-height-rule: exactly;">
                                                        <strong>WARNING: RISK OF SERIOUS DISORDERS </strong>
                                                    </td>
                                                </tr>
                                                <tr>
                                                    <td class="montserrat-regular" align="left" valign="top"
                                                        style="padding: 0 15px 15px; font-family: 'Montserrat', Arial, Helvetica, sans-serif; font-size: 14px; line-height: 17px; color: #000000; font-weight: 400; font-style: normal; border-collapse: collapse; mso-height-rule: exactly;">
                                                        
                                                        <strong>
                                                            Interferon alfa products may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Patients should be monitored closely with
                                                            periodic clinical and laboratory evaluations. Therapy should be withdrawn in patients with persistently severe or worsening signs or symptoms of these conditions. In many, but not all
                                                            cases, these disorders resolve after stopping therapy.
                                                        </strong>
                                                    </td>
                                                </tr>
                                            </table>
                                        </td>
                                    </tr>

                                    <!--Contraindications-->
                                    <tr>
                                        <td class="mobile-side-padding montserrat-regular" align="left" valign="top"
                                            style="padding: 20px 45px 0;font-family: 'Montserrat', Arial, Helvetica, sans-serif; font-size: 14px; line-height: 17px; color: #000000; font-weight: 400; font-style: normal; border-collapse: collapse; mso-height-rule: exactly;">
                                            <strong style="color: #244C5A; font-weight: 600;">CONTRAINDICATIONS</strong>
                                        </td>
                                    </tr>
                                    <!--Contraindication List-->
                                    <tr>
                                        <td class="mobile-side-padding montserrat-regular" align="left" valign="top" style="padding: 10px 45px 0; border-collapse: collapse; mso-height-rule: exactly;">
                                            <table cellspacing="0" cellpadding="0" border="0" width="100%" role="presentation" align="center"
                                                style="border-collapse:collapse; mso-table-lspace: 0pt; mso-table-rspace: 0pt;">
                                                <tr>
                                                    <td width="8" align="center" valign="top"
                                                        style="font-family: 'Montserrat', Arial, Helvetica, sans-serif; font-size: 14px; line-height: 16px; color: #f2a732; font-weight: 800; font-style: normal; border-collapse: collapse; mso-height-rule: exactly; vertical-align: top;">
                                                        &#8226;</td>
                                                    <td align="left" valign="top"
                                                        style="padding: 0 0 7px 5px; font-family: 'Montserrat', Arial, Helvetica, sans-serif; font-size: 14px; line-height: 17px; color: #000000; font-weight: 400; font-style: normal; border-collapse: collapse; mso-height-rule: exactly;">
                                                        Existence of or history of severe depression, suicidal ideation, or suicide attempt </td>
                                                </tr>
                                                <tr>
                                                    <td width="8" align="center" valign="top"
                                                        style="font-family: 'Montserrat', Arial, Helvetica, sans-serif; font-size: 14px; line-height: 16px; color: #f2a732; font-weight: 800; font-style: normal; border-collapse: collapse; mso-height-rule: exactly; vertical-align: top;">
                                                        &#8226;</td>
                                                    <td align="left" valign="top"
                                                        style="padding: 0 0 7px 5px; font-family: 'Montserrat', Arial, Helvetica, sans-serif; font-size: 14px; line-height: 17px; color: #000000; font-weight: 400; font-style: normal; border-collapse: collapse; mso-height-rule: exactly;">
                                                        Hypersensitivity to interferons or any inactive ingredients  </td>
                                                </tr>
                                                <tr>
                                                    <td width="8" align="center" valign="top"
                                                        style="font-family: 'Montserrat', Arial, Helvetica, sans-serif; font-size: 14px; line-height: 16px; color: #f2a732; font-weight: 800; font-style: normal; border-collapse: collapse; mso-height-rule: exactly; vertical-align: top;">
                                                        &#8226;</td>
                                                    <td align="left" valign="top"
                                                        style="padding: 0 0 7px 5px; font-family: 'Montserrat', Arial, Helvetica, sans-serif; font-size: 14px; line-height: 17px; color: #000000; font-weight: 400; font-style: normal; border-collapse: collapse; mso-height-rule: exactly;">
                                                        Moderate or severe hepatic impairment </td>
                                                </tr>
                                                <tr>
                                                    <td width="8" align="center" valign="top"
                                                        style="font-family: 'Montserrat', Arial, Helvetica, sans-serif; font-size: 14px; line-height: 16px; color: #f2a732; font-weight: 800; font-style: normal; border-collapse: collapse; mso-height-rule: exactly; vertical-align: top;">
                                                        &#8226;</td>
                                                    <td align="left" valign="top"
                                                        style="padding: 0 0 7px 5px; font-family: 'Montserrat', Arial, Helvetica, sans-serif; font-size: 14px; line-height: 17px; color: #000000; font-weight: 400; font-style: normal; border-collapse: collapse; mso-height-rule: exactly;">
                                                        History or presence of active serious or untreated autoimmune disease</td>
                                                </tr>
                                                <tr>
                                                    <td width="8" align="center" valign="top"
                                                        style="font-family: 'Montserrat', Arial, Helvetica, sans-serif; font-size: 14px; line-height: 16px; color: #f2a732; font-weight: 800; font-style: normal; border-collapse: collapse; mso-height-rule: exactly; vertical-align: top;">
                                                        &#8226;</td>
                                                    <td align="left" valign="top"
                                                        style="padding: 0 0 7px 5px; font-family: 'Montserrat', Arial, Helvetica, sans-serif; font-size: 14px; line-height: 17px; color: #000000; font-weight: 400; font-style: normal; border-collapse: collapse; mso-height-rule: exactly;">
                                                        History of transplantation and receiving immunosuppressant agents </td>
                                                </tr>
                                            </table>
                                        </td>
                                    </tr>

                                    <!--Warnings and precautions-->
                                    <tr>
                                        <td class="mobile-side-padding montserrat-regular" align="left" valign="top"
                                            style="padding: 18px 45px 0;font-family: 'Montserrat', Arial, Helvetica, sans-serif; font-size: 14px; line-height: 17px; color: #000000; font-weight: 400; font-style: normal; border-collapse: collapse; mso-height-rule: exactly;">
                                            <strong style="color: #244C5A; font-weight: 600;">WARNINGS AND PRECAUTIONS</strong>
                                        </td>
                                    </tr>
                                    <!--Warnings and precautions List-->
                                    <tr>
                                        <td class="mobile-side-padding montserrat-regular" align="left" valign="top" style="padding: 10px 45px 0; border-collapse: collapse; mso-height-rule: exactly;">
                                            <table cellspacing="0" cellpadding="0" border="0" width="100%" role="presentation" align="center"
                                                style="border-collapse:collapse; mso-table-lspace: 0pt; mso-table-rspace: 0pt;">
                                                <tr>
                                                    <td width="8" align="center" valign="top"
                                                        style="font-family: 'Montserrat', Arial, Helvetica, sans-serif; font-size: 14px; line-height: 16px; color: #f2a732; font-weight: 800; font-style: normal; border-collapse: collapse; mso-height-rule: exactly; vertical-align: top;">
                                                        &#8226;</td>
                                                    <td align="left" valign="top"
                                                        style="padding: 0 0 7px 5px; font-family: 'Montserrat', Arial, Helvetica, sans-serif; font-size: 14px; line-height: 17px; color: #000000; font-weight: 400; font-style: normal; border-collapse: collapse; mso-height-rule: exactly;">
                                                        Depression and Suicide: Closely monitor patients for any symptoms of psychiatric disorders and, if needed, consider psychiatric consultation and treatment or dosage modifications as listed in the full prescribing information.</td>
                                                </tr>
                                                
                                                
                                                <tr>
                                                    <td width="8" align="center" valign="top"
                                                        style="font-family: 'Montserrat', Arial, Helvetica, sans-serif; font-size: 14px; line-height: 16px; color: #f2a732; font-weight: 800; font-style: normal; border-collapse: collapse; mso-height-rule: exactly; vertical-align: top;">
                                                        &#8226;</td>
                                                    <td align="left" valign="top"
                                                        style="padding: 0 0 7px 5px; font-family: 'Montserrat', Arial, Helvetica, sans-serif; font-size: 14px; line-height: 17px; color: #000000; font-weight: 400; font-style: normal; border-collapse: collapse; mso-height-rule: exactly;">
                                                        Endocrine Toxicity: Do not use BESREMi in patients with active serious or untreated endocrine disorders associated with autoimmune disease. Evaluate thyroid function in patients who develop symptoms suggestive of thyroid disease during BESREMi therapy. Discontinue BESREMi in patients who develop endocrine disorders that cannot be adequately managed during treatment with BESREMi. </td>
                                                </tr>
                                                <tr>
                                                    <td width="8" align="center" valign="top"
                                                        style="font-family: 'Montserrat', Arial, Helvetica, sans-serif; font-size: 14px; line-height: 16px; color: #f2a732; font-weight: 800; font-style: normal; border-collapse: collapse; mso-height-rule: exactly; vertical-align: top;">
                                                        &#8226;</td>
                                                    <td align="left" valign="top"
                                                        style="padding: 0 0 7px 5px; font-family: 'Montserrat', Arial, Helvetica, sans-serif; font-size: 14px; line-height: 17px; color: #000000; font-weight: 400; font-style: normal; border-collapse: collapse; mso-height-rule: exactly;">
                                                        Cardiovascular Toxicity: Patients with a history of cardiovascular disorders should be closely monitored for cardiovascular toxicity during BESREMi therapy. Avoid use of BESREMi in patients with severe or unstable cardiovascular disease or recent stroke or myocardial infarction. </td>
                                                </tr>

                                                <tr>
                                                    <td width="8" align="center" valign="top"
                                                        style="font-family: 'Montserrat', Arial, Helvetica, sans-serif; font-size: 14px; line-height: 16px; color: #f2a732; font-weight: 800; font-style: normal; border-collapse: collapse; mso-height-rule: exactly; vertical-align: top;">
                                                        &#8226;</td>
                                                    <td align="left" valign="top"
                                                        style="padding: 0 0 7px 5px; font-family: 'Montserrat', Arial, Helvetica, sans-serif; font-size: 14px; line-height: 17px; color: #000000; font-weight: 400; font-style: normal; border-collapse: collapse; mso-height-rule: exactly;">
                                                        Decreased Peripheral Blood Counts: Monitor complete blood counts at baseline, during titration, and every 3-6 months during the maintenance phase. </td>
                                                </tr>
                                                
                                                <tr>
                                                    <td width="8" align="center" valign="top"
                                                        style="font-family: 'Montserrat', Arial, Helvetica, sans-serif; font-size: 14px; line-height: 16px; color: #f2a732; font-weight: 800; font-style: normal; border-collapse: collapse; mso-height-rule: exactly; vertical-align: top;">
                                                        &#8226;</td>
                                                    <td align="left" valign="top"
                                                        style="padding: 0 0 7px 5px; font-family: 'Montserrat', Arial, Helvetica, sans-serif; font-size: 14px; line-height: 17px; color: #000000; font-weight: 400; font-style: normal; border-collapse: collapse; mso-height-rule: exactly;">
                                                        Pancreatitis/Colitis/Pulmonary Toxicity: Interrupt BESREMi treatment in patients with possible pancreatitis, colitis, or pulmonary toxicity and evaluate promptly. Consider discontinuation of BESREMi in patients with confirmed pancreatitis or who show signs or symptoms of serious ulcerative or hemorrhagic colitis, or who develop pulmonary infiltrates or pulmonary function impairment. </td>
                                                </tr>
                                                
                                            
                                                <tr>
                                                    <td width="8" align="center" valign="top"
                                                        style="font-family: 'Montserrat', Arial, Helvetica, sans-serif; font-size: 14px; line-height: 16px; color: #f2a732; font-weight: 800; font-style: normal; border-collapse: collapse; mso-height-rule: exactly; vertical-align: top;">
                                                        &#8226;</td>
                                                    <td align="left" valign="top"
                                                        style="padding: 0 0 7px 5px; font-family: 'Montserrat', Arial, Helvetica, sans-serif; font-size: 14px; line-height: 17px; color: #000000; font-weight: 400; font-style: normal; border-collapse: collapse; mso-height-rule: exactly;">
                                                        Ophthalmologic Toxicity: Advise patients to have eye examinations before and during treatment. Discontinue BESREMi in patients who develop new or worsening eye disorders.</td>
                                                </tr>
                                                <tr>
                                                    <td width="8" align="center" valign="top"
                                                        style="font-family: 'Montserrat', Arial, Helvetica, sans-serif; font-size: 14px; line-height: 16px; color: #f2a732; font-weight: 800; font-style: normal; border-collapse: collapse; mso-height-rule: exactly; vertical-align: top;">
                                                        &#8226;</td>
                                                    <td align="left" valign="top"
                                                        style="padding: 0 0 7px 5px; font-family: 'Montserrat', Arial, Helvetica, sans-serif; font-size: 14px; line-height: 17px; color: #000000; font-weight: 400; font-style: normal; border-collapse: collapse; mso-height-rule: exactly;">
                                                        Hyperlipidemia/Hepatotoxicity/Renal Toxicity: Monitor serum triglycerides, liver enzymes, hepatic function, and serum creatinine at baseline and during therapy. Avoid use of BESREMi in patients with eGFR &lt;30 mL/min. Discontinue BESREMi in patients with persistently marked elevated triglycerides, evidence of hepatic decompensation, or if renal impairment develops during treatment.
                                                    </td>
                                                </tr>
                                                
                                                
                                                <tr>
                                                    <td width="8" align="center" valign="top"
                                                        style="font-family: 'Montserrat', Arial, Helvetica, sans-serif; font-size: 14px; line-height: 16px; color: #f2a732; font-weight: 800; font-style: normal; border-collapse: collapse; mso-height-rule: exactly; vertical-align: top;">
                                                        &#8226;</td>
                                                    <td align="left" valign="top"
                                                        style="padding: 0 0 7px 5px; font-family: 'Montserrat', Arial, Helvetica, sans-serif; font-size: 14px; line-height: 17px; color: #000000; font-weight: 400; font-style: normal; border-collapse: collapse; mso-height-rule: exactly;">
                                                        Dental and Periodontal Toxicity: Patients should have good oral hygiene and regular dental examinations.</td>
                                                </tr>

                                                <tr>
                                                    <td width="8" align="center" valign="top"
                                                        style="font-family: 'Montserrat', Arial, Helvetica, sans-serif; font-size: 14px; line-height: 16px; color: #f2a732; font-weight: 800; font-style: normal; border-collapse: collapse; mso-height-rule: exactly; vertical-align: top;">
                                                        &#8226;</td>
                                                    <td align="left" valign="top"
                                                        style="padding: 0 0 7px 5px; font-family: 'Montserrat', Arial, Helvetica, sans-serif; font-size: 14px; line-height: 17px; color: #000000; font-weight: 400; font-style: normal; border-collapse: collapse; mso-height-rule: exactly;">
                                                        Dermatologic Toxicity: Consider discontinuation of BESREMi if clinically significant dermatologic toxicity occurs. </td>
                                                </tr>
                                                <tr>
                                                    <td width="8" align="center" valign="top"
                                                        style="font-family: 'Montserrat', Arial, Helvetica, sans-serif; font-size: 14px; line-height: 16px; color: #f2a732; font-weight: 800; font-style: normal; border-collapse: collapse; mso-height-rule: exactly; vertical-align: top;">
                                                        &#8226;</td>
                                                    <td align="left" valign="top"
                                                        style="padding: 0 0 7px 5px; font-family: 'Montserrat', Arial, Helvetica, sans-serif; font-size: 14px; line-height: 17px; color: #000000; font-weight: 400; font-style: normal; border-collapse: collapse; mso-height-rule: exactly;">
                                                        Driving and Operating Machinery: BESREMi may impact the ability to drive and use machinery. Patients should not drive or use heavy machinery until they know how BESREMi affects their abilities. Patients who experience dizziness, somnolence, or hallucination during BESREMi therapy should avoid driving or using machinery.</td>
                                                </tr>
                                                <tr>
                                                    <td width="8" align="center" valign="top"
                                                        style="font-family: 'Montserrat', Arial, Helvetica, sans-serif; font-size: 14px; line-height: 16px; color: #f2a732; font-weight: 800; font-style: normal; border-collapse: collapse; mso-height-rule: exactly; vertical-align: top;">
                                                        &#8226;</td>
                                                    <td align="left" valign="top"
                                                        style="padding: 0 0 7px 5px; font-family: 'Montserrat', Arial, Helvetica, sans-serif; font-size: 14px; line-height: 17px; color: #000000; font-weight: 400; font-style: normal; border-collapse: collapse; mso-height-rule: exactly;">
                                                        Embryo-Fetal Toxicity: Based on the mechanism of action, BESREMi can cause fetal harm when administered to a pregnant woman. Obtain a pregnancy test in females of reproductive potential prior to initiating treatment with BESREMi. Advise females of reproductive potential to use an effective method of contraception during treatment with BESREMi and for at least 8 weeks after the final dose. Advise women not to breastfeed during treatment and for 8 weeks after the final dose.</td>
                                                </tr>
                                            </table>
                                        </td>
                                    </tr>

                                    <!--Adverse reactions-->
                                    <tr>
                                        <td class="mobile-side-padding montserrat-regular" align="left" valign="top"
                                            style="padding: 18px 45px 0;font-family: 'Montserrat', Arial, Helvetica, sans-serif; font-size: 14px; line-height: 17px; color: #000000; font-weight: 400; font-style: normal; border-collapse: collapse; mso-height-rule: exactly;">
                                            <strong style="color: #244C5A; font-weight: 600;">ADVERSE REACTIONS</strong>
                                        </td>
                                    </tr>
                                    <tr>
                                        <td class="mobile-side-padding montserrat-regular" align="left" valign="top"
                                            style="padding: 10px 45px 0;font-family: 'Montserrat', Arial, Helvetica, sans-serif; font-size: 14px; line-height: 17px; color: #000000; font-weight: 400; font-style: normal; border-collapse: collapse; mso-height-rule: exactly;">
                                            The most common adverse reactions reported in &gt;40% of patients were influenza-like illness, arthralgia, fatigue, pruritus, nasopharyngitis, and musculoskeletal pain.
                                        </td>
                                    </tr>
                                    <!--DRUG INTERACTIONS-->
                                    <tr>
                                        <td class="mobile-side-padding montserrat-regular" align="left" valign="top"
                                            style="padding: 18px 45px 0;font-family: 'Montserrat', Arial, Helvetica, sans-serif; font-size: 14px; line-height: 17px; color: #000000; font-weight: 400; font-style: normal; border-collapse: collapse; mso-height-rule: exactly;">
                                            <strong style="color: #244C5A; font-weight: 600;">DRUG INTERACTIONS</strong> 
                                        </td>
                                    </tr>
                                    <tr>
                                        <td class="mobile-side-padding montserrat-regular" align="left" valign="top"
                                            style="padding: 10px 45px 0;font-family: 'Montserrat', Arial, Helvetica, sans-serif; font-size: 14px; line-height: 17px; color: #000000; font-weight: 400; font-style: normal; border-collapse: collapse; mso-height-rule: exactly;">
                                            Patients on BESREMi who are receiving concomitant drugs which are CYP450 substrates with a narrow therapeutic index should be monitored to inform the need for dosage modification. Avoid use with myelosuppressive agents, narcotics, hypnotics, or sedatives, and monitor patients receiving the combination for effects of excessive CNS toxicity.
                                        </td>
                                    </tr>
                                    <tr>
                                        <td class="mobile-side-padding montserrat-regular" align="left" valign="top"
                                            style="padding: 25px 45px 0;font-family: 'Montserrat', Arial, Helvetica, sans-serif; font-size: 14px; line-height: 17px; color: #000000; font-weight: 400; font-style: normal; border-collapse: collapse; mso-height-rule: exactly;">
                                            To report SUSPECTED ADVERSE REACTIONS, contact PharmaEssentia at 1&#8209;80&zwj;0&#8209;99&zwj;9&#8209;24&zwj;49 or FDA at 1&#8209;8&zwj;00&#8209;FDA&#8209;10&zwj;88 or <a href="https://www.fda.gov/medwatch"><span style="color: #000000;">w&zwj;w&zwj;w&zwj;.&zwj;fda&zwj;.&zwj;gov/medwatch</span></a>  

                                        </td> 
                                    </tr>
                                    <!--Please see full Prescribing Information, including Boxed Warning. -->
                                    <tr>
                                        <td class="mobile-side-padding montserrat-regular" align="left" valign="top"
                                            style="padding: 25px 45px 0;font-family: 'Montserrat', Arial, Helvetica, sans-serif; font-size: 14px; line-height: 17px; color: #000000; font-weight: 400; font-style: normal; border-collapse: collapse; mso-height-rule: exactly;">
                                            Please see full <a href="https://us.pharmaessentia.com/downloads/Besremi_USPI_ENG.pdf" target="_blank"><u style="color: #244C5A;">Prescribing Information</u></a>, including Boxed Warning.  

                                        </td>
                                    </tr>

                                    <!--References-->
                                    <tr>
                                        <td class="mobile-side-padding montserrat-regular" align="left" valign="top"
                                            style="padding:25px 45px 0;font-family: 'Montserrat', Arial, Helvetica, sans-serif; font-size: 12px; line-height: 15px; color: #000000; font-weight: 400; font-style: normal; border-collapse: collapse; mso-height-rule: exactly;">
                                            <strong>References: 1.</strong> Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines<sup>&reg;</sup>) for Myeloproliferative Neoplasms V.1.20&zwj;25. &copy; National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed February 25, 20&zwj;25. To view the most recent and complete version of the guidelines, go online to NCCN&zwj;.&zwj;or&zwj;g. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. <strong>2.</strong>&nbsp;BESREMi. Package insert. PharmaEssentia Corporation; 20&zwj;24. <strong>3.</strong>&nbsp;Chen CY, Chuang WL, Qin A, et al. A phase 3 clinical trial validating the potency and safety of an innovative, extra-long-acting interferon in chronic hepatitis C. <em>JGH Open</em>. 2022;6(11):782-791. doi:10.1002/jgh3.128&zwj;25 <strong>4.</strong>&nbsp;Data on file. PharmaEssentia Corporation.
                                        </td>
                                    </tr> 

                                    <tr>
                                        <td class="mobile-side-padding montserrat-regular" align="left" valign="top" style="padding: 25px 45px 0px; border-collapse: collapse; mso-height-rule: exactly; ">
                                            <a href="https://hq.pharmaessentia.com/" target="_blank">
                                                <img src="https://production-stage.s3.us-east-1.amazonaws.com/emails/Spectrum/BESREMi/May-Test/EM3/images/PEC-logo.png" width="150" alt="PharmaEssentia"
                                                    style="display: block; text-align: center; color: #000000; font-family: Arial, Helvetica, sans-serif; font-size:14px; line-height:16px; font-weight: bold; margin:0; padding:0; border:none; height: auto; max-width: 100%;"
                                                    border="0" />
                                            </a>
                                        </td>
                                    </tr>

                                    <!--Copyright-->
                                    <tr>
                                        <td class="mobile-side-padding montserrat-regular" align="left" valign="top"
                                            style="padding:25px 45px 0;font-family: 'Montserrat', Arial, Helvetica, sans-serif; font-size: 12px; line-height: 15px; color: #000000; font-weight: 400; font-style: normal; border-collapse: collapse; mso-height-rule: exactly;">
                                            &copy;&nbsp;2025 PharmaEssentia Corporation. All rights reserved. <br />
                                            BESREMi, the BESREMi logo, and PharmaEssentia are registered trademarks of PharmaEssentia Corporation, and the PharmaEssentia logo is a trademark of PharmaEssentia Corporation.
                                            <br />
                                            US-BSRM-2500&zwj;079 (v1&zwj;.0) 06/20&zwj;25
                                        </td>
                                    </tr>
    
                                </table>



                                <table cellspacing="0" cellpadding="0" border="0" width="100%" role="presentation" align="center" style="border-collapse:collapse; mso-table-lspace: 0pt; mso-table-rspace: 0pt;">
                                    <tr>
                                        <td class="mobile-side-padding montserrat-regular" align="center" valign="top"
                                            style="padding: 30px 45px 0px;font-family: 'Montserrat', Arial, Helvetica, sans-serif; font-size: 10px; line-height: 12px; color: #000000; font-weight: 400; font-style: normal; border-collapse: collapse; mso-height-rule: exactly; text-align: center;">
                                            <!-- TABLE - ALIGN: center, VALIGN top -->
                                            <table width="100%" role="presentation" border="0" cellspacing="0" cellpadding="0" align="center"
                                                style="border-collapse: collapse; mso-table-lspace: 0pt; mso-table-rspace: 0pt;border-top: 1px solid #244C5A;">
                                                <tr>
                                                    <td class="mobile-side-padding montserrat-regular" align="center" valign="top"
                                                        style="padding: 30px 0px 50px;font-family: 'Montserrat', Arial, Helvetica, sans-serif; font-size: 10px; line-height: 12px; color: #244C5A; font-weight: 400; font-style: normal; border-collapse: collapse; mso-height-rule: exactly; text-align: center;">
                                                        <strong style="color: #244C5A; font-weight: 600;">To stop receiving emails from your PharmaEssentia Representative, you can <a
                                                                href="{{unsubscribe_product_link[,Unsubscribe_vod.Unsubscribe_Identifier_vod]}}" target="_blank"><u style="color: #244C5A;">unsubscribe</u></a></strong>.
                                                    </td>
                                                </tr>
                                            </table>
                                
                                        </td>
                                
                                        <!--END ISI-->
                                </table>

                                <!-- CONTENT ENDS  HERE -->
                            </td>
                        </tr>
                    </table>
                    <!--===================-->
                    <!-- WRAPPER TABLE END -->
                    <!--===================-->
                </td>
            </tr>
        </table>
        <!-- BODY TABLE / -->
    </div>
</body>

</html>